The optimization of recombinant antibody production in Chinese hamster ovary (CHO) cells presents a paramount challenge with the biopharmaceutical industry. Various strategies are employed maximize antibody titer, including process parameter optimization, cell line development, and adoption of perfusion systems. Fine-tuning culture conditions pla